Vaxil Bio Ltd.
VXLLF
$0.13
$0.122,021.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.03% | 73.05% | 154.87% | 65.69% | -57.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.03% | 20.00% | 200.44% | 69.92% | -67.51% |
| Operating Income | 13.03% | -20.00% | -200.44% | -69.92% | 67.51% |
| Income Before Tax | 184.69% | -13.49% | -182.20% | -71.77% | 67.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 184.69% | -13.49% | -182.20% | -71.77% | 67.51% |
| Earnings from Discontinued Operations | 184.31% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 184.92% | -13.49% | -182.20% | -71.77% | 62.12% |
| EBIT | 13.03% | -20.00% | -200.44% | -69.92% | 67.51% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 184.73% | -13.38% | -181.43% | -72.37% | 62.03% |
| Normalized Basic EPS | 184.29% | -13.27% | -169.23% | -46.43% | 67.59% |
| EPS Diluted | 184.73% | -13.38% | -181.43% | -72.37% | 62.03% |
| Normalized Diluted EPS | 184.29% | -13.27% | -169.23% | -46.43% | 67.59% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |